Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
Mary Elizabeth Cox1, Jennifer Rowell1, Leonor Corsino1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durha...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-01-01
|
| Series: | Drug, Healthcare and Patient Safety |
| Online Access: | http://www.dovepress.com/dipeptidyl-peptidase-4-inhibitors-in-the-management-of-type-2-diabetes-a3931 |
| _version_ | 1828423211459543040 |
|---|---|
| author | Mary Elizabeth Cox Jennifer Rowell Leonor Corsino et al |
| author_facet | Mary Elizabeth Cox Jennifer Rowell Leonor Corsino et al |
| author_sort | Mary Elizabeth Cox |
| collection | DOAJ |
| description | Mary Elizabeth Cox1, Jennifer Rowell1, Leonor Corsino1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.Keywords: type 2 diabetes, pharmacotherapy, DPP-4 inhibitor, sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin |
| first_indexed | 2024-12-10T15:58:56Z |
| format | Article |
| id | doaj.art-8a87265e9c8e46339f4bb560179027f7 |
| institution | Directory Open Access Journal |
| issn | 1179-1365 |
| language | English |
| last_indexed | 2024-12-10T15:58:56Z |
| publishDate | 2010-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug, Healthcare and Patient Safety |
| spelling | doaj.art-8a87265e9c8e46339f4bb560179027f72022-12-22T01:42:31ZengDove Medical PressDrug, Healthcare and Patient Safety1179-13652010-01-012010default719Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacyMary Elizabeth CoxJennifer RowellLeonor Corsinoet alMary Elizabeth Cox1, Jennifer Rowell1, Leonor Corsino1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.Keywords: type 2 diabetes, pharmacotherapy, DPP-4 inhibitor, sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptinhttp://www.dovepress.com/dipeptidyl-peptidase-4-inhibitors-in-the-management-of-type-2-diabetes-a3931 |
| spellingShingle | Mary Elizabeth Cox Jennifer Rowell Leonor Corsino et al Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy Drug, Healthcare and Patient Safety |
| title | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| title_full | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| title_fullStr | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| title_full_unstemmed | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| title_short | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| title_sort | dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes safety tolerability and efficacy |
| url | http://www.dovepress.com/dipeptidyl-peptidase-4-inhibitors-in-the-management-of-type-2-diabetes-a3931 |
| work_keys_str_mv | AT maryelizabethcox dipeptidylpeptidase4inhibitorsinthemanagementoftype2diabetessafetytolerabilityandefficacy AT jenniferrowell dipeptidylpeptidase4inhibitorsinthemanagementoftype2diabetessafetytolerabilityandefficacy AT leonorcorsino dipeptidylpeptidase4inhibitorsinthemanagementoftype2diabetessafetytolerabilityandefficacy AT etal dipeptidylpeptidase4inhibitorsinthemanagementoftype2diabetessafetytolerabilityandefficacy |